Successful treatment of pure red cell aplasia of an 88-year-old case with cyclosporin A and erythropoietin after thymectomy

An 88-year-old Japanese female with pure red cell aplasia was treated safely and effectively by a combination of thymectomy, cyclosporin A, and erythropoietin. The thymoma was histologically classified as lymphocytic type or cortical type, which are uncommon in cases of a thymoma accompanied by pure red cell aplasia. Immunohistochemical analysis of the thymoma and bone marrow revealed a predominance of CD8+ cells. Thymectomy alone was ineffective, but cyclosporin A treatment subsequent to thymectomy was safe and effective and resulted in the disappearance of a Vβ12 bearing T cell clone in the bone marrow. Additional treatment with erythropoietin enhanced the effects of cyclosporin A and recovered the patient’s hemoglobin to normal levels. The beneficial effect of cyclosporin A may be attributed not to a broad immunomodulatory effect, but to a local effect on a limited T cell subset.

Case Report

On April 16, 2002, an 88-year-old female was admitted to the hospital with complaints of easy fatigability and exertional dyspnea. She had been previously medicated for hypertension before admission. Anemic palpebral conjunctiva and pretibial edema was noticed upon admission. Laboratory findings upon admission were the following: white blood cells, 4880 × 10^6/L (neutrophils, 36%; eosinophils, 1%; basophils, 1%; monocytes, 4%; lymphocytes, 58%); red blood cells, 131 × 10^6/L; hemoglobin (Hb), 4.4 g/dL; hematocrit, 12.9%; platelets, 25.7 × 10^6/L; and reticulocytes, 0.1%. Other measurements were: serum creatinine, 0.9 mg/dL; fasting serum blood sugar, 111 mg/dL; hemoglobin A1c, 7.10% (normal range: 4.0-5.8%); serum iron, 171 microgram/dL. Parvovirus infection in this case was unlikely, since IgM specific for parvovirus B19 was undetectable and polymerase chain reaction (PCR) analysis for viral DNA was negative. Haptoglobin was within normal range, and the direct and indirect Coombs’ test was negative. Levels of CD55 and CD59, markers for paroxysmal nocturnal hemoglobinuria (PNH), were within the normal limits. Erythropoietin (EPO) was 2860 mU/mL (normal range: 8-36 mU/mL). Examination of the patient’s bone marrow showed severe hypoplasia specific for erythroid lines (erythroid, 0%) but leukemic blasts and no abnormality in other cell lineages, suggesting a diagnosis of pure red cell aplasia. Antinuclear antibody titer was x640 (homogeneous and speckled pattern). The HLA-DRB1 alleles included 0101 and 0405. Chest roentgenogram revealed an enlarged heart with a cardiothoracic ratio of 54% and the presence of pleural effusion, suggesting impaired cardiac function by severe anemia. Computerized chest tomography revealed a relatively large thymic mass (3 × 3 cm) for her advanced age. Although all previous medication prior to the admission was withdrawn, anemia was not improved. In order to suppress the suspected autoimmune condition, a thymectomy was performed. The pathological diagnosis of the thymic mass was thymoma of lymphocytic type (the Lattes-Bernatz classification) or cortical type (the Muller-Hermelink classification), corresponding to type B of the WHO Classification.14 We did not observe recovery of Hb levels after the thymectomy. We next administered cyclosporin A (CsA), which has been found to be the most effective agent in single treatments. CsA was administered at 125 to 250 mg/day to keep serum CsA levels between 200 and 300 ng/mL, respectively. Oral hydration of 1.5-2.0 liters a day was supplied simultaneously. Reticulocyte numbers recovered within one week. We also observed a gradual rise in Hb levels that reached 8.5-9.5 g/dL. EPO reduced into a normal level (18.8IU/L). The CsA treatment did not result in any observable complication. The pretibial edema, enlarged heart, and pleural effusion gradually disappeared. However, the patient still complained of mild exertional dyspnea and dorsal edema. For this reason, we began EPO injections at 6000 IU/week. Approximately one month later, the patient’s Hb levels rose to 14.0±0.5 g/dL, at which point she felt no exertional dyspnea and had no apparent edema. At this stage, erythroid cells in the bone marrow recovered to 15%. She has been followed as an outpatient for 11 months without relapse. The accompaniment of PRCA by a thymoma and increased antinuclear antibody (ANA) titer suggested that an autoimmune mechanism triggered the PRCA. The ANA titer, however, was not reduced after CsA treatment. Immunohistochemical staining of the thymoma tissue revealed expanded CD8+ positive cells in the cortical zone and normal numbers of CD4+, CD20+; and CD56-positive cells.

Flow cytometric analysis of bone marrow cells showed that the CD4/CD8 ratio of lymphocytes was low, but within the normal range. After thymectomy, the CD4/CD8 ratio increased without remission of anemia. Unexpectedly, however, the ratio decreased with CsA administration even during the remission period. This effect of CsA would result from a localized influence rather than an inhibitory effect on the entire CD8+ population in bone marrow.

To analyze further the alteration of T cell-mediated autoimmunity by CsA treatment, the T cell receptor (TCR) repertoire in the thymus and bone marrow were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) with TCR beta chain subfamily-specific primers and a subsequent single-strand conformation polymorphism (SSCP) analysis, according to methods previously described.1 One of the SSCP bands for Vβ12, which presumably corresponds to a T cell clone in the bone marrow, disappeared after the start of CsA administration (Figure 1).
Discussion

With reduced reticulocyte levels and erythroid-specific hypoplasia accompanying high erythropoietin levels, PRCA was diagnosed under the medication-free condition of the patient. Immunosuppressive therapy is currently an accepted treatment for PRCA.10% to 15% of the PRCA patients are found to have thymoma, usually spindle cell (the Lattes-Bernatz classification) or medullary type (the Muller-Hermelink classification).4 Thus far, it is uncertain if the accompaniment of a histopathologically unusual thymoma corresponds to a specific feature of this case, such as CD8 dominance, or bias of Vbeta12 clones.

Levels of circulating CD45RA+ CD8+ T cells were reported to be increased in thymoma patients and to decrease after thymectomy.9 The observed cortical CD8+ accumulation in this case may reflect activation of cytotoxic T cells against erythroid precursor cells. Increase of the CD4/CD8 ratio by CsA therapy has been reported in autoimmune-associated diseases, e.g., aplastic anemia with autoimmune thyroiditis, and pure red cell aplasia.10-12 In the present case, CsA reduced the CD4/CD8 ratio in bone marrow. This discrepancy might reflect a heterogeneous pathogenesis of pure red cell aplasia. In this case, CsA did not ameliorate broad CD8 dominance.

A bias in T cell receptor Vbeta repertoire has also been reported in various autoimmune conditions such as rheumatoid arthritis, Sjogren’s syndrome, myasthenia gravis, pure red cell aplasia, and multiple sclerosis.13-18 T cell clonality, as evidenced by clonal Vbeta rearrangement, was reported in PRCA patients.19 The disappearance of a Vbeta12 clone after CsA treatment supports the idea that immunosuppression of T cells resulted in a significant responsiveness to CsA therapy.20 In the present case, CD8+ clones were involved in erythropoietic impairment. Taken together, unknown CD8+ clones are likely involved in pathogenesis of PRCA in an HLA-DRB*0405 restricted manner.

Thymectomy, even in high-aged cases, is considered beneficial for either directly improving the disease or increasing its sensitivity to immunosuppressive treatment. A combination of thymectomy and CsA, however, was not enough to recover the patient’s hematocrit to normal levels. This could partially have resulted from CsA itself, as one side effect of CsA is to suppress the level of endogenous erythropoietin.20,21 This is the basis for providing additional EPO treatment. EPO therapy has been shown to be effective in treating PRCA accompanied by underlying autoimmunity such as systemic lupus erythematosus. The expectation is that the supplied EPO will compete with autoantibody by binding the erythropoietin receptor on immature erythroid cells.22 In the present case, EPO could have provided a direct therapeutic effect in overcoming the speculative underlying autoimmunity. Further similar cases are necessary to confirm the effectiveness of the present combination therapy for the high-aged PRCA population.

References


Toyoki Maeda et al.

Figure 1. RT-SSCP analysis of T cell receptor Vbeta12 of thymoma and bone marrow of the patient. Two specimens were obtained separately from the patient’s thymoma and subjected to RT-SSCP analysis. SSCP results of Vbeta12 to Vbeta20 are shown. Note that a band indicated by the arrow disappears after the commencement of CsA administration (see text and Figure 3).

| 62 | haematologica/the hematology journal | 2004; 89(online) |


